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Background aims. Dendritic cell (DC)-based immunotherapy has shown potential to counteract autoimmunity in multiple
sclerosis (MS).Methods.We compared the phenotype and T-cell stimulatory capacity of in vitro generated monocyte-derived
DC from MS patients with those from healthy controls. Results. Except for an increase in the number of C-C chemokine
receptor 7eexpressing DC from MS patients, no major differences were found between groups in the expression of
maturation-associated membrane markers or in the in vitro capacity to stimulate autologous T cells. Conclusions. Our ob-
servations may pave the way for the development of patient-tailored DC-based vaccination strategies to treat MS.
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Multiple sclerosis (MS) is a chronic inﬂammatory
disease of the central nervous system (1). The disease
is characterized by a heterogeneous disease course
and can be either progressive (i.e., chronically-pro-
gressive [CP-MS]), or the disease symptoms can be
interrupted by periods with partial or complete
remission (i.e., relapsing-remitting [RR-MS]). The
majority of patients display the latter disease course
at disease onset. However, after a moderate level of
disability is reached, two thirds of RR-MS patients
proceed into a secondary-progressive disease (1). A
minority of patients (10e15%) shows a progressive
accumulation of disability from disease onset (i.e.,
primary-progressive [PP-MS]) (1e3). Although MS
is considered to be a predominantly T-cell-mediated
autoimmune disease, recent ﬁndings from several
groups suggest that innate immune cells, such as
dendritic cells (DCs), control and direct the auto-
reactive immune response.Correspondence: Nathalie Cools, PhD, Laboratory of Experimental Hematology
and Health Sciences, University of Antwerp, Antwerp University Hospital (UZA),
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cells that bridge innate immune functions with the
induction of adaptive immunity. They orchestrate
the outcome of immune responses through a com-
bination of incoming signals. DCs capture, process
and present (self-)antigens (i.e., signal 1) in combi-
nation with costimulatory molecules (i.e., signal 2) to
naive T cells. Upon encounter of so-called danger
signals, DCs undergo a complex maturation process
that includes upregulated expression of co-
stimulatory markers; low expression levels of these
molecules are representative of steady-state condi-
tions. In the absence of signal 2, T cells undergo
anergy or deletion, resulting in T cell tolerance (4).
Furthermore, a new class of pathways delivering
tolerogenic signals (i.e., co-inhibitory pathways) has
been identiﬁed and may be of importance in the in-
duction of Tregs (5). Finally, by secreting a number of
cytokines (i.e., signal 3), DCs direct naive T cells to
differentiate into various T helper (Th) subsets (4,6,7)., Vaccine & Infectious Disease Institute (Vaxinfectio), Faculty of Medicine
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Table I. Clinical details of the study population.
Code patients Gender Age MS type EDSS score Code healthy controls Gender Age
UPN 001 F 46 RR 2.5 UPN 036 M 56
UPN 002 F 54 CP 4 UPN 037 M 53
UPN 003 F 46 CP 6.5 UPN 038 F 51
UPN 004 F 39 RR 4 UPN 039 F 56
UPN 005 F 62 CP 6.5 UPN 040 F 48
UPN 006 M 62 CP 6.5 UPN 041 M 46
UPN 007 M 59 CP 7.5 UPN 042 M 44
UPN 008 F 47 RR 2 UPN 043 F 53
UPN 009 F 51 CP 5 UPN 044 F 47
UPN 010 M 48 CP 6.5 UPN 045 F 44
UPN 011 M 52 CP 7.5 UPN 046 F 54
UPN 012 M 56 CP 5.5 UPN 047 F 56
UPN 013 M 44 CP 7 UPN 048 M 55
UPN 014 F 51 CP 6.5 UPN 049 F 48
UPN 015 M 46 CP 6.5 UPN 050 F 23
UPN 016 M 52 CP 6.5 UPN 051 F 44
UPN 017 F 54 RR 2.5 UPN 052 M 38
UPN 018 F 22 RR 0 UPN 053 F 23
UPN 019 F 52 RR 1.5 UPN 054 M 54
UPN 020 F 38 RR 0 UPN 055 M 54
UPN 021 M 43 CP 8 UPN 056 M 55
UPN 022 M 68 CP 6.5 UPN 057 F 38
UPN 023 F 43 CP 8 UPN 058 F 24
UPN 024 F 53 RR 6.5 UPN 059 M 39
UPN 025 F 63 CP 8 UPN 060 F 31
UPN 026 M 72 CP 7.5 UPN 061 M 72
UPN 027 F 74 CP 8 UPN 062 F 29
UPN 028 M 60 CP 8.5 UPN 063 F 66
UPN 029 M 55 CP 5 UPN 064 F 38
UPN 030 M 55 CP 5
UPN 031 F 28 RR 1
UPN 032 F 43 RR 4
UPN 033 M 53 CP 5.5
UPN 034 F 54 CP 3.5
















EDSS, expanded disability status scale; F, female; M, male; UPN, unique patient number.
Monocyte-derived dendritic cells from patients with multiple sclerosis 1025This so-called T cell polarization will deﬁne the reg-
ulatory or effector function of stimulated T cells (8,9)
and underscores the crucial role of DCs in directing
the T cell balance. If the expression of one of these
signals is impaired or dysfunctional, the outcome of
the T cell response will likely be affected.
Given their central role in maintaining the
balance between immunity and tolerance, ex vivoe
generated immature and/or tolerogenic monocytee
derived DCs have been proposed as a tool to
reestablish tolerance in autoimmune disorders
mediated by self-reactive T cells that escaped thymic
deletion (10,11). In this context, a milestone study
by Dhodapkar et al. (12) has previously demon-
strated that a single injection of antigen-loaded
immature DCs was able to inhibit antigen-speciﬁc
T cell induction in healthy subjects. More studies
have revealed the safety and potential clinical beneﬁtof therapeutic vaccination with tolerogenic DCs in
patients (13,14), but to date information with regard
to the in vitro generation and function of DCs from
patients with MS is limited. In addition, we and
others have demonstrated that circulating myeloid
and plasmacytoid DCs of MS patients display pro-
inﬂammatory characteristics compared with steady-
state DCs from healthy controls (15e18). In this
study, monocyte-derived DCs from MS patients
were compared with those from controls with regard
to membrane phenotype and autologous T cell
stimulatory capacity.Methods
MS patients, diagnosed according to McDonald
criteria (19), were recruited by the Departments of
Neurology of the National MS Center (Melsbroek,
Table II. Expression of membrane markers of DCs of MS patients




iDC mDC iDC mDC iDC mDC
DC-SIGN MFI 287 228 *** 280 191 *** ns ns
% 92 88 *** 89 80 *** ns <0.01
HLA-DR MFI 99 165 *** 127 184 ** ns ns
% 89 95 * 97 96 <0.05 ns
CD80 MFI 13 29 *** 16 33 *** ns ns
% 26 58 *** 26 54 *** ns ns
CD83 MFI 13 45 *** 18 50 *** ns ns
% 2 33 *** 5 32 *** ns ns
CD86 MFI 214 569 *** 229 526 *** ns ns
% 97 99 *** 98 99 * <0.05 ns
CCR7 MFI 15 33 *** 22 35 *** ns ns
% 1 10 ** 9 16 * <0.05 <0.05
Immature monocyte-derived DCs were obtained after differenti-
ation of CD14þ cells with IL-4 and granulocyte macrophage
colony-stimulating factor. On day 6 of cell culture, DCs were
activated with a cocktail of pro-inﬂammatory cytokines
(i.e., mDC) or left untreated (i.e., iDC). The DC phenotype was
analyzed on day 7 by multiparametric ﬂow cytometry. Results are
shown as mean value of 17 MS patients and 16 HCs. P values
comparing the difference within one group (iDC vs. mDC) are
indicated by an asterisk and validated using a paired t-test (*P <
0.05; **P < 0.01; ***P < 0.001). P values comparing DCs of
patients with those of controls are shown in the last column. These
observations were validated using an unpaired t-test.
CCR, C-C chemokine receptor; CD, cluster of differentiation; DC-
SIGN, DC-speciﬁc intercellular adhesion molecule-3-grabbing
non-integrin; HCs, healthy control subjects; HLA, human leuko-
cyte antigen; MFI, mean ﬂuorescence intensity; ns, not signiﬁcant.
1026 A. H. Nuyts et al.Belgium) and of the Antwerp University Hospital
(Edegem, Belgium). Thirty-ﬁve patients (16 men
and 19 women) with a median age of 52 (range:
22e74 years), a median Expanded Disability Status
Scale (EDSS) score of 5 (range: 0e8.5) and without
MS-related medication at the time of sampling were
included (Table I). Twenty-nine age- and gender-
matched healthy individuals were included as control
subjects. All subjects gave informed consent in
accordance with the declaration of Helsinki, and the
study protocol was approved by the local ethics
committees of the National MS Center and of the
Antwerp University Hospital.
CD14þ monocytes were isolated from heparin-
ized peripheral blood as described previously (8). The
CD14-depleted cell fraction (i.e., peripheral blood
lymphocytes [PBLs]) was cryopreserved and stored
at 80C. To generate monocyte-derived DCs
(moDCs), 1e2  106 CD14þ cells/mL were differ-
entiated in the presence of 25 ng/mL interleukin (IL)-
4 and 17.5 ng/mL granulocyte macrophage colony-
stimulating factor. On day 6, DCs were stimulated for
24 hours by adding a cocktail of pro-inﬂammatory
cytokines consisting of 100 U/mL IL-1, 500 U/mL
IL-6, 2.5 ng/mL tumour necrosis factor (TNF)-a and
107 M prostaglandin E2 (PGE2, Prostin E2) for the
generation of mature DCs (mDCs) or left untreated
for the generation of immature DCs (iDCs). On day
7, immunophenotyping of DCs was preformed using
the following murine anti-human antibodies: anti-C-
C chemokine receptor (CCR)7, anti-CD83, anti-
CD80, anti-CD86, anti-DC-SIGN and anti-HLA-
DR. For analytical ﬂow cytometry, at least 104 events
were analyzed using a BD FACScan (BD Bio-
sciences, Erembodegem, Belgium).
For T cell activation, PBLs were cultured in
presence or absence of iDCs or mDCs. After 7 days,
induction of CD4þCD25þ T cells was determined
using the following murine anti-human antibodies:
anti-CD8, anti-CD3, anti-CD4 and anti-CD25. Dead
cells were excluded using a LIVE/DEAD ﬁxable Dead
Cell Stain kit. At least 5  104 CD3þCD4þCD8-
lymphocytes were analyzed on a Cyﬂow ML ﬂow
cytometer (Partec GmbH, Münster, Germany). For
myelin-speciﬁc T cell induction, PBLs were stimu-
lated with a pool of myelin-derived peptides (i.e.,
myelin oligodendrocyte glycoprotein [MOG]1e22,
MOG34e56, MOG64e86, MOG74e96 and myelin basic
protein (MBP)84e102 and MBP143e168) (20) in pres-
ence or absence of iDCs or mDCs. After 5 days,
interferon (IFN)-g secretion was evaluated by IFN-g
enzyme-linked immunosorbent spot assay (ELISpot)
following antigenic restimulation. Non-restimulated
PBLs served as a negative control. For the deﬁnition
of a MOG/MBP responder, the following criteria were
followed: per 106 PBLs stimulated with maturemoDCs, the mean antigen-speciﬁc spot count must
be greater than or equal to 20 spots and at least three
times as high as background.
Comparisons were validated using a paired t-test
or one-way analysis of variance for observations
within one subject and using an unpaired t-test for
independent observations. Odds ratios were calcu-
lated with a Fisher’s exact test. All statistics were
calculated using GraphPad version 5 software
(Prism, La Jolla, CA, USA). A P value <0.05 was
considered statistically signiﬁcant (*) and a P
value <0.01 (**) and <0.001 (***) as highly statis-
tically signiﬁcant.Results
Higher expression of CCR7 in mo DCs from MS patients
MoDCs of MS patients and of healthy controls were
phenotypically characterized using multiparametric
ﬂow cytometry. A modest but statistically signiﬁcant
increased relative proportion of iDCs expressing the
costimulatory molecule CD86 and the antigen-pre-
senting molecule HLA-DR was found in MS patients
(Table II), whereas no differences for the expression
Figure 1. T cell stimulatory capacity of monocyte-derived DCs from MS patients compared with moDCs from healthy controls. (A) Flow
cytometric determination of activated T cell frequency as indicated by CD4þCD25þ expression. Autologous PBLs were analyzed after a
7-day DC/T cell co-culture. (B) The DC-mediated expansion of PBLs was calculated by dividing the frequency CD4þCD25þ following
DC stimulation with the baseline CD4þCD25þ frequency (i.e., PBLs alone). Results are shown for 11 MS patients (ﬁlled bars) and
8 healthy control subjects (open bars). (C) Detection of DC-mediated IFN-g secretion by PBLs using ELISpot after a 5-day culture of
autologous PBLs in presence or absence of iDCs or mDCs. (D) The DC-mediated expansion of the IFN-g secretion was calculated by
dividing the number of spot-forming cells (SFC) following DC stimulation with the baseline number of SFC (i.e., PBL alone). Results are
shown for 23 MS patients (ﬁlled bars) and 22 healthy controls (open bars). (E) Detection of myelin-speciﬁc IFN-g secretion by ELISpot
analysis. Following stimulation of autologous PBLs with a pool of myelin-derived peptides in presence or absence of iDCs or mDCs, PBLs
were restimulated using a myelin-derived peptide pool. (F) The DC-mediated expansion of the myelin-speciﬁc IFN-g secretion was
calculated by dividing the number of spot-forming cells (SFC) following DC stimulation with the baseline number of SFC (i.e., PBLs alone).
Results are shown as the number of antigen-induced SFC corrected for the negative control for 11 antigen-responding MS patients (ﬁlled
bars) and for 6 antigen-responding healthy control subjects (open bars). All results are expressed as mean þ standard error of mean (SEM)
or as Tukey whiskers boxplots. Comparisons were validated using a paired t-test or one-way analysis of variance for observations within one
subject and using an unpaired t-test for independent observations. *P < 0.05; **P < 0.01; ***P < 0.001.
Monocyte-derived dendritic cells from patients with multiple sclerosis 1027of CD83, CD80 and DC-SIGN could be detected
compared with immature moDC from healthy con-
trols. Following stimulation with a pro-inﬂammatory
cytokine cocktail initiating the maturation process of
moDCs, similar numbers of moDC expressing
CD80, CD83, CD86 and HLA-DR were found in
MS patients and healthy controls. No differences
were observed between RR-MS and CP-MS patients
(data not shown). However, DC SIGNepositive
mature moDCs were signiﬁcantly lower in RR-MS
but not in CP-MS patients compared with healthy
controls. Interestingly, both immature and mature
moDCs from RR-MS but not CP-MS patients arecharacterized by a signiﬁcantly higher proportion of
CCR7-expressing cells compared with those from
controls (Table II).Autologous DC-mediated T cell stimulation reveals no
differences between MS patients and healthy controls
First, the overall autologous T cell stimulatory capa-
city of in vitroegenerated DCs from MS patients and
age- and gender-matched control subjects was evalu-
ated. For this, autologous PBLs of MS patients and
healthy control subjectswere stimulated for 7dayswith
immature or mature moDCs. Next, the frequency of
1028 A. H. Nuyts et al.CD4þ T cells expressing the activation marker CD25
was determined as a measure of T cell activation. Our
results show that expression of the activation marker
CD25 is signiﬁcantly induced after stimulation with
mDCs (Figure 1A), indicating expansion of a signiﬁ-
cantly greater proportion of these cells compared with
stimulation with iDCs (Figure 1B). Importantly, DCs
of MS patients display a similar capacity to induce
T cell activation to that of controls. In addition, no
difference in the number of IFN-g spot-forming cells
was observed betweenMSpatients andhealthy control
subjects (Figure 1C and 1D).MoDCs of MS patients and healthy controls induce
similar myelin-speciﬁc IFN-g secretion
Finally, we investigated the antigen-speciﬁc T cell
stimulatory capacity of DCs from MS patients and
healthy control subjects. PBLs were stimulated with a
pool of myelin-derived peptides in the presence or
absence of iDCs and mDCs in an autologous context.
Subsequently, myelin-speciﬁc IFN-g secretion was
determined by IFN-g ELISpot following antigen
restimulation. No signiﬁcant differences in myelin-
speciﬁc T cell-stimulatory capacity between DCs of
MS patients and of control subjects after antigenic
restimulation could be detected (Figure 1E and 1F).
Of interest, odds ratio showed no signiﬁcant difference
in the number of MOG/MBP responders between MS
patients and healthy control subjects: 11 of 32 MS
patients (27%) and 6 of 20 healthy control subjects
(30%) displayed a deﬁned myelin-speciﬁc response.Discussion
Until now, conﬂicting data have been reported
regarding the membrane phenotype of monocyte-
derived DCs from MS patients. Although some au-
thors have described a reduced expression of CD83
(21) and a decreased frequency of CD86-positive
DCs (22), others reported no differences in MS pa-
tients (21,23,24). In contrast, we report a modest,
but statistically signiﬁcant, increased relative pro-
portion of iDCs from MS patients expressing the
costimulatory molecule CD86 and the antigen-
presenting molecule HLA-DR. However, no differ-
ences were found between the expression levels of
DC-characteristic membrane markers per cell be-
tween patients and control subjects. Although it re-
mains to be established if the observed difference in
the expression proﬁle of costimulatory markers of in
vitro generated DCs between MS patients and con-
trols is of physiological relevance, discrepancies be-
tween different studies could also be attributed to
treatment effects (21,23,24) or genetic variability (25).Furthermore, and to our knowledge for the ﬁrst
time, we observed a signiﬁcantly higher proportion of
CCR7-expressing DCs from MS patients compared
with control subjects. Increased CCR7 expression
may result in improved migration to the lymph nodes,
which would be required for therapeutic vaccination.
Indeed, Verdijk et al. have previously shown that less
than 4% of migratory DCs are sufﬁcient to induce
antigen-speciﬁc immunologic responses in the
draining lymph nodes (26). Additionally, because
the process of DC maturation involves, among
others actions, redistribution in the expression of
chemokine receptors, this suggests a more activated
state of MS-derived DCs. This may result in
stronger T cell activation by a CCR7-mediated in-
crease of the cell surface and life span of DCs and
may be detrimental in a clinical setting where in-
duction of tolerance is the aim (27).
To determine if this was the case, we evaluated for
the ﬁrst time the autologous T cell stimulatory ca-
pacity of monocyte-derived DCs generated from MS
patients and demonstrate no signiﬁcant differences
with those of control subjects in two independent
read-out methods. Other authors demonstrated no
effect on proliferation (21,28), but increased secretion
of IFN-g (28), in an allogeneic mixed lymphocyte
reaction following stimulation with DCs from MS
patients compared with control subjects.
Autoreactive T cell responses against myelin an-
tigens are considered to play a primary role in the
pathogenesis ofMS and have been extensively studied
in patients with MS and control subjects (20,29e34).
Here, we analyzed T cell reactivity to a panel of
MOG- andMBP-derived synthetic peptides that were
previously demonstrated to be immunodominant
(20,35e37) and not HLA-DR restricted (20,32,38).
Furthermore, these peptides correspond to epitopes
shown to be encephalitogenic in several strains of
rodents and non-human primates (39). No signiﬁcant
differences could be detected by IFN-g ELISpot be-
tween autologous myelin-speciﬁc T cell stimulatory
capacity of DCs from MS patients and control sub-
jects, following antigenic restimulation, in agreement
with current scientiﬁc evidence (20,29e34).
In conclusion, monocyte-derived DCs from MS
patients are functionally comparable to those from
control subjects. For this, our data suggest no con-
traindications to use iDCs of MS patients and that
they thus may be suitable for tolerance-inducing im-
munotherapies (40,41). Nevertheless, a major
concern may relate to the risk of in vivo activation,
particularly in response to any underlying inﬂamma-
tory micro-environment, and this has tempered the
use of tolerogenic DC in vivo by the need to preserve
the tolerogenic phenotype. For this, strategies to
harness the tolerogenic capacity of DCs have been
Monocyte-derived dendritic cells from patients with multiple sclerosis 1029developed. In vitro treatment of monocyte-derived
DCs with IFN-ß, glatiramer acetate (24,28), vitamin
D3 (23) and IL-10 (28) are capable ofmodulatingDC
phenotype and/or function, making these molecules
attractive biological agents for future studies.Acknowledgments
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